Show simple item record

dc.contributor.authorKolstad, A.
dc.contributor.authorIllidge, Timothy M
dc.contributor.authorBolstad, N.
dc.contributor.authorSpetalen, S.
dc.contributor.authorMadsbu, U.
dc.contributor.authorStokke, C.
dc.contributor.authorBlakkisrud, J.
dc.contributor.authorLondalen, A.
dc.contributor.authorO'Rourke, N.
dc.contributor.authorBeasley, M.
dc.contributor.authorJurczak, W.
dc.contributor.authorFagerli, U. M.
dc.contributor.authorKascak, M.
dc.contributor.authorBayne, M.
dc.contributor.authorObr, A.
dc.contributor.authorDahle, J.
dc.contributor.authorRojkjaer, L.
dc.contributor.authorPascal, V.
dc.contributor.authorHolte, H.
dc.date.accessioned2020-10-06T13:33:47Z
dc.date.available2020-10-06T13:33:47Z
dc.date.issued2020en
dc.identifier.citationKolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091-101.en
dc.identifier.pmid32877524en
dc.identifier.doi10.1182/bloodadvances.2020002583en
dc.identifier.urihttp://hdl.handle.net/10541/623335
dc.description.abstractFor patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20-based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. 177Lu-lilotomab satetraxetan is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) which was investigated in a phase 1/2a study in 74 patients with relapsed/refractory indolent non-Hodgkin B-cell lymphoma, including 57 patients with follicular lymphoma (FL). To improve targeting of 177Lu-lilotomab satetraxetan to tumor tissue and decrease hematologic toxicity, its administration was preceded by the anti-CD20 monoclonal antibody rituximab and the "cold" anti-CD37 antibody lilotomab. The most common adverse events (AEs) were reversible grade 3/4 neutropenia (31.6%) and thrombocytopenia (26.3%) with neutrophil and platelet count nadirs 5 to 7 weeks after RIT. The most frequent nonhematologic AE was grade 1/2 nausea (15.8%). With a single administration, the overall response rate was 61% (65% in patients with FL), including 30% complete responses. For FL with ≥2 prior therapies (n = 37), the overall response rate was 70%, including 32% complete responses. For patients with rituximab-refractory FL ≥2 prior therapies (n = 21), the overall response rate was 67%, and the complete response rate was 24%. The overall median duration of response was 13.6 months (32.0 months for patients with a complete response). 177Lu-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches. This trial was registered at www.clinicaltrials.gov as #NCT01796171.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1182/bloodadvances.2020002583en
dc.titlePhase 1/2a study of Lu-177-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphomaen
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norwayen
dc.identifier.journalBlood Advancesen
dc.description.noteen]
refterms.dateFOA2020-10-07T13:12:18Z


Files in this item

Thumbnail
Name:
32877524.pdf
Size:
1.278Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record